BREAKING NEWS: Regeneron says its antibody cocktail reduces the risk of contracting Covid by more than 80% for at least EIGHT MONTHS
- Regeneron say its antibody cocktail REGEN-COV reduces the risk of contracting COVID-19 by 81.6% two to eight months after it is administered
- The drug was authorized last year as a treatment for the virus but has since been expanded so it can be used as a prophylactic
Regeneron Pharmaceuticals Inc announced on Monday that its antibody cocktail can severely slash the risk of being infected with COVID-19 for up to eight months.
The combo therapy, REGEN-COV, was approved in November 2020 for emergency use to treat people with mild-to-moderate COVID-19 cases in the U.S.
But the U.S. Food and Drug Administration (FDA) expanded authorization in July 2021 so the drug can also be used as a preventive treatment.
Late-stage trial data showed a single dose can lower the risk of contracting Covid by 81.6 percent between two and six-months after the cocktail is administered.
Regeneron say its antibody cocktail REGEN-COV (above) reduces the risk of contracting COVID-19 by 81.6% two to eight months after it is administered
This is a breaking news story and will be updated.